Tags

Type your tag names separated by a space and hit enter

Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.
Clin J Am Soc Nephrol. 2009 Feb; 4(2):337-44.CJ

Abstract

BACKGROUND AND OBJECTIVES

Chronic kidney disease (CKD) has recently assumed epidemic proportion, becoming a troubling emerging cause of morbidity, especially if it progresses to terminal stage (ESRD). The authors aimed to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL), a novel specific biomarker of acute kidney injury, could predict the progression of CKD.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS

Serum and urinary NGAL levels, together with a series of putative progression factors, were evaluated in a cohort of 96 patients (mean age: 57 +/- 16 years) affected by nonterminal CKD (eGFR > or =15 ml/min/1.73 m(2)) of various etiology. Progression of CKD, assessed as doubling of baseline serum creatinine and/or onset of ESRD, was evaluated during follow-up.

RESULTS

At baseline, both serum and urinary NGAL were inversely, independently, and closely related to eGFR. After a median follow-up of 18.5 mo (range 1.01 to 20), 31 patients (32%) reached the composite endpoint. At baseline, these patients were significantly older and showed increased serum creatinine, calcium-phosphate product, C-reactive protein, fibrinogen, daily proteinuria, and NGAL levels, whereas eGFR values were significantly lower. Univariate followed by multivariate Cox proportional hazard regression analysis showed that urinary NGAL and sNGAL predicted CKD progression independently of other potential confounders, including eGFR and age.

CONCLUSION

In patients with CKD, NGAL closely reflects the entity of renal impairment and represents a strong and independent risk marker for progression of CKD.

Authors+Show Affiliations

Department of Internal Medicine, University of Messina, Messima, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19176795

Citation

Bolignano, Davide, et al. "Neutrophil Gelatinase-associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease." Clinical Journal of the American Society of Nephrology : CJASN, vol. 4, no. 2, 2009, pp. 337-44.
Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(2):337-44.
Bolignano, D., Lacquaniti, A., Coppolino, G., Donato, V., Campo, S., Fazio, M. R., Nicocia, G., & Buemi, M. (2009). Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clinical Journal of the American Society of Nephrology : CJASN, 4(2), 337-44. https://doi.org/10.2215/CJN.03530708
Bolignano D, et al. Neutrophil Gelatinase-associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease. Clin J Am Soc Nephrol. 2009;4(2):337-44. PubMed PMID: 19176795.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. AU - Bolignano,Davide, AU - Lacquaniti,Antonio, AU - Coppolino,Giuseppe, AU - Donato,Valentina, AU - Campo,Susanna, AU - Fazio,Maria Rosaria, AU - Nicocia,Giacomo, AU - Buemi,Michele, Y1 - 2009/01/28/ PY - 2009/1/30/entrez PY - 2009/1/30/pubmed PY - 2009/6/12/medline SP - 337 EP - 44 JF - Clinical journal of the American Society of Nephrology : CJASN JO - Clin J Am Soc Nephrol VL - 4 IS - 2 N2 - BACKGROUND AND OBJECTIVES: Chronic kidney disease (CKD) has recently assumed epidemic proportion, becoming a troubling emerging cause of morbidity, especially if it progresses to terminal stage (ESRD). The authors aimed to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL), a novel specific biomarker of acute kidney injury, could predict the progression of CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serum and urinary NGAL levels, together with a series of putative progression factors, were evaluated in a cohort of 96 patients (mean age: 57 +/- 16 years) affected by nonterminal CKD (eGFR > or =15 ml/min/1.73 m(2)) of various etiology. Progression of CKD, assessed as doubling of baseline serum creatinine and/or onset of ESRD, was evaluated during follow-up. RESULTS: At baseline, both serum and urinary NGAL were inversely, independently, and closely related to eGFR. After a median follow-up of 18.5 mo (range 1.01 to 20), 31 patients (32%) reached the composite endpoint. At baseline, these patients were significantly older and showed increased serum creatinine, calcium-phosphate product, C-reactive protein, fibrinogen, daily proteinuria, and NGAL levels, whereas eGFR values were significantly lower. Univariate followed by multivariate Cox proportional hazard regression analysis showed that urinary NGAL and sNGAL predicted CKD progression independently of other potential confounders, including eGFR and age. CONCLUSION: In patients with CKD, NGAL closely reflects the entity of renal impairment and represents a strong and independent risk marker for progression of CKD. SN - 1555-905X UR - https://www.unboundmedicine.com/medline/citation/19176795/Neutrophil_gelatinase_associated_lipocalin__NGAL__and_progression_of_chronic_kidney_disease_ DB - PRIME DP - Unbound Medicine ER -